Last updated: April 1, 2026
Case Overview
Vanda Pharmaceuticals Inc. filed a patent infringement lawsuit against Apotex Inc. in the District of District of Columbia, case number 1:24-cv-01344. The case concerns alleged infringement related to Vanda’s patent covering a formulation of iloperidone, marketed as Fanapt®. The litigation stems from Apotex’s development of a generic version of the drug prior to patent expiration.
Patent At Issue
Vanda holds U.S. Patent No. 8,543,047, granted October 1, 2013, titled "Stable Pharmaceutical Composition Containing Iloperidone." The patent claims specific methods and compositions related to stable formulations of iloperidone with particular focus on crystalline and amorphous states. The patent is set to expire on October 1, 2032, subject to possible extensions or patent term adjustments.
Allegations
Vanda asserts that Apotex’s generic candidate infringes specific claims of the '047 patent, notably those related to the stability of the crystalline form of iloperidone. Vanda maintains that Apotex's development and expected market introduction violate its patent rights, infringing on the formulation and stability claims.
Case Progression
- Filing Date: March 21, 2024
- Preliminary Motions: Apotex filed a motion to dismiss on the grounds of non-infringement and patent invalidity under 35 U.S.C. § 101 and § 112.
- Discovery: Both parties engaged in document production, expert disclosures, and claim construction proceedings expected to span 12-18 months.
- Trial Schedule: Pending court scheduling, with a tentative trial date set for late 2025.
Legal Issues
Patent Validity
- Written Description and Enablement: Apotex challenges whether the '047 patent sufficiently describes how to produce and maintain the claimed stable crystalline form.
- Inventiveness: The defendant questions whether the patent claims involve an inventive step over prior art, including earlier formulations of iloperidone.
Patent Infringement
- Literal Infringement: Vanda claims Apotex's generic infringes on claims covering specific crystalline forms and stability methods.
- Doctrine of Equivalents: Vanda may assert infringement under the doctrine if Apotex’s formulation differs in minor but functionally equivalent ways.
Implications for Stakeholders
- Vanda: Seeks a preliminary or permanent injunction to prevent Apotex’s market entry and damages for prior infringement.
- Apotex: Likely to pursue invalidity defenses and possibly argue that the patent fails to meet statutory requirements or is anticipated by existing prior art.
- Market Impact: A ruling favoring Vanda could delay entry of generic iloperidone, maintaining higher prices for Fanapt®. A ruling favoring Apotex could enable earlier market entry, affecting sales and generic pricing.
Market and Legal Context
- Several generic applicants have signaled intentions to challenge Vanda’s patent through Paragraph IV certifications, aiming for early market entry upon patent expiry.
- The case exemplifies ongoing patent litigation strategic to the biosimilar and generic pharmaceutical sectors, particularly around complex crystalline formulations.
- Recent case law suggests courts are scrutinizing formulation patents for patentable non-obviousness, especially where prior art discloses similar crystalline forms.
Key Takeaways
- The case emphasizes the importance of patent claims directed toward specific crystalline forms and stability modifications.
- Court proceedings are expected to clarify the scope of patent validity and infringement, influencing the timing of generic market entry.
- The outcome could set a precedent regarding patent enforceability on pharmaceutical stability formulations.
FAQs
-
What specific claims of the '047 patent are in dispute?
The dispute centers on claims related to the crystalline form's stability and manufacturing methods for iloperidone.
-
When is a decision expected?
The case is in early stages; a roughly 12-18 month timeline for discovery and claim construction is typical, with a trial possibly in late 2025.
-
How can Apotex defend against patent infringement?
Apotex might argue that the patent claims are invalid due to insufficient written description, obviousness over prior art, or non-infringement by their formulation.
-
What happens if the patent is invalidated?
Apotex would be free to launch its generic version without risk of infringement claims on the same patent.
-
What are the broader implications of this case?
It highlights the ongoing legal battle over crystalline formulation patents and their role in delaying generic competition.
References
[1] U.S. Patent and Trademark Office. (2013). Patent No. 8,543,047.
[2] Vanda Pharmaceuticals Inc. v. Apotex Inc., 1:24-cv-01344 (D.D.C., 2024).
